While CD1c has not been studied as a viable biomarker for DLBCL immunotherapy yet, in our study, we explored the relationship between CD1c expression and prognosis in DLBCL using bioinformatics analysis, revealing that low CD1c expression is indicative of better prognosis. The gene discussed is CD1C; the disease is diffuse large B-cell lymphoma.